SCYNEXIS Inc. (NASDAQ:SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS announced positive results from a Phase 1 clinical study evaluating SCY-247, its second-generation triterpenoid antifungal compound. The candidate is being developed for the treatment and prevention of invasive fungal infections to provide the therapeutic advantages of both an oral and an intravenous/IV formulation.
The favorable results show orally administered SCY-247 can achieve target exposures for efficacy with favorable tolerability, and at doses lower than their first-generation fungerp, which may offer a tolerability advantage. The Phase 1 study was conducted in healthy participants to assess the safety, tolerability, and pharmacokinetics of orally administered SCY-247. SCY-247 was well tolerated across all SAD and MAD cohorts.
The positive safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-247. Further details from this study are expected to be presented at an upcoming scientific meeting.
SCYNEXIS Inc. is a biotechnology company that develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
